The number of Americans taking a dangerous combination of opioids and benzodiazepines--which are a group of drugs routinely prescribed for pain, insomnia, and anxiety increased by 250 percent in the past 15 years.
There was an 850 percent increase in patients taking both benzodiazepines or Z-drugs, which act in a similar way to benzodiazepines, revealed a new study published in the journal Sleep.
The research by Dr. Nicholas Vozoris, an associate scientist at the Li Ka Shing Knowledge Institute of St. Michael's Hospital in Toronto, relies on data from eight National Health and Nutrition Examination Survey (NHANES) cycles between 1999 and 2014. It found the prevalence of benzodiazepine and opioid co-usage in the United States in 2014 was 1.36 percent, while the prevalence of benzodiazepine and Z-drug co-usage was 0.47 percent.
Dr. Vozoris found the increases in co-usage very concerning given that these drug-use patterns are associated with increased risks for serious adverse outcomes including breathing problems and death.
"The FDA has gone as far as to issue its strongest form of safety warning about this suboptimal prescribing practice and mixing of opioids and benzodiazepines."
The 1.36 percent prevalence of benzodiazepine and opioid co-usage translated to about 4.3 million people, while the 0.47 percent prevalence of benzodiazepine and Z-drug co-usage amounted to about 1.5 million people.
Dr. Vozoris said he's seen a lot of confusion about benzodiazepines and Z-drugs among both patients and other medical professionals.
Commonly prescribed benzodiazepines include alprazolam, clonazepam and lorazepam while Z-drugs include zaleplon, zolpidem and zopiclone.
"There are doctors and members of the public often not realizing that Z-drugs are very similar in action to benzodiazepine drugs -- sometimes patients get put on both a benzo and a Z-drug and think they're two very different drugs," Dr. Vozoris said.
"I wanted to understand the trends in use of such worrisome drug combinations and which types of individuals were more likely to receive such drug combinations."